国药集团一致药业股份有限公司 2016 年第一季度报告全文
China National Accord Medicines Corporation Ltd.
First Quarterly Report 2016
April 2016
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd. (hereinafter referred to as the Company) and its
directors, supervisors and senior executives should guarantee the reality,
accuracy and completion of the quarterly report, there are no any fictitious
statements, misleading statements or important omissions carried in this report,
and shall take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong person in charge of the Company, Wei Pingxiao, person in
charger of accounting works and Wang Ying, person in charger of accounting
organ (accounting officer) hereby confirm that the Financial Report of this
Quarterly Report is authentic, accurate and complete.
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section II. Main financial data and changes of shareholders
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 7,053,846,519.17 6,261,714,700.23 12.65%
Net profit attributable to shareholders of
199,027,472.31 197,026,237.82 1.02%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 187,445,696.09 192,315,542.07 -2.53%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
-100,461,465.99 182,179,606.70 -155.14%
activities(RMB)
Basic earnings per share (RMB/Share) 0.549 0.543 1.10%
Diluted earnings per share (RMB/Share) 0.549 0.543 1.10%
Weighted average ROE 3.58% 4.05% -0.47%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 14,172,328,814.96 13,218,349,735.31 7.22%
Net assets attributable to shareholder of
5,652,382,580.33 5,453,393,694.55 3.65%
listed company (RMB)
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Mainly because the subsidiary
Gains/losses from the disposal of non-current asset (including the Guangxi Logistics disposed the
9,117,952.96
write-off that accrued for impairment of assets) house property and obtained
compensation for demolition;
Governmental subsidy reckoned into current gains/losses (not
Mainly due to the various special
including the subsidy enjoyed in quota or ration according to
4,043,684.40 grants received in the current
national standards, which are closely relevant to enterprise’s
period;
business)
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Mainly because the bad debts of
Reversal of impairment reserve for account receivable with receivables withdrawn alone in
953,105.02
separate impairment testing the previous years have been
taken back in the current period;
Other non-operating income and expenditure except for the
1,110,983.48
aforementioned items
Less: impact on income tax 3,514,045.71
Impact on minority shareholders’ equity (post-tax) 129,903.93
Total 11,581,776.22 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total preference shareholders
Total common shareholders
with voting rights recovered at
16,413
at the end of report period end of reporting period (if
applicable)
Top ten shareholders
Amount of Number of share pledged/frozen
Shareholder’s Nature of Proportion of Amount of shares
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm Group State-owned legal
51.00% 184,942,291 74,482,543
Co., Ltd. person
National Social Domestic non
Security Fund state-owned legal 2.01% 7,298,555
106 combination person
Domestic non
China Securities
state-owned 1.97% 7,132,757
Finance Co., Ltd.
Corporation
HTHK/CMG
FSGUFP-CMG Foreign
1.94% 7,032,720
FIRST STATE Corporation
CHINA
国药集团一致药业股份有限公司 2016 年第一季度报告全文
GROWTH FD
VALUE
Foreign
PARTNERS 1.42% 5,138,568
Corporation
CLASSIC FUND
Domestic non
CITIC Securities
state-owned 1.38% 5,008,637
Co., Ltd.
Corporation
National Social Domestic non
Security Fund state-owned legal 1.32% 4,783,965
116 combination person
New China Life
Insurance Co.,
Ltd. – Bonus – Domestic non
Individual state-owned 1.16% 4,199,772
bonuses - Corporation
-018L-FH002
Shen
Central Huijin State-owned
1.05% 3,804,400
Investment Ltd. Corporation
China Life
Insurance Co.,
Ltd. – tradition – Domestic non
general insurance state-owned 1.03% 3,750,090
products - Corporation
005L-CT001
Shen
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
National Social Security Fund 106 RMB ordinary
7,298,555 7,298,555
combination shares
RMB ordinary
China Securities Finance Co., Ltd. 7,132,757 7,132,757
shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
Domestically
VALUE PARTNERS CLASSIC
5,138,568 listed foreign 5,138,568
FUND
shares
国药集团一致药业股份有限公司 2016 年第一季度报告全文
RMB ordinary
CITIC Securities Co., Ltd. 5,008,637 5,008,637
shares
National Social Security Fund 116 RMB ordinary
4,783,965 4,783,965
combination shares
New China Life Insurance Co., Ltd.
RMB ordinary
– Bonus – Individual bonuses - 4,199,772 4,199,772
shares
-018L-FH002 Shen
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition – general insurance 3,750,090 3,750,090
shares
products - 005L-CT001 Shen
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the above shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Divided into assets held for sale: a decrease of 2,456,900 yuan compared with the beginning of the period, with a growth rate of
-100.00%, mainly because the underlying assets have been completed in the current transaction;
2. Other current assets: a decrease of 7,106,200 yuan compared with the beginning of the period, with a growth rate of -36.52%,
mainly because the value added tax retained has reduced in the current period;
3. Employee pay payable: a decrease of 68,188,800 yuan compared with the beginning of the period, with a growth rate of -41.50%,
mainly because employee remuneration withdrawn in the previous year has been issued in the current period;
4. Taxes payable: an increase of 39,752,200 yuan compared with the beginning of the period, with a growth rate of 54.56%, mainly
due to the sales growth in current period resulting in an increase of provision for income tax;
5. Non-current liabilities due within one year: an increase of 2,075,200 yuan compared with the beginning of the period, with a
growth rate of 38.11%, mainly due to the increase of member points in the current period;
6. Non-operating expenses: a decrease of 151,700 yuan on a year-on-year basis, with a growth rate of -46.84%, mainly because the
loss of non-current assets disposed in the current period has reduced on a year-on-year basis;
7. Tax refunds received: an increase of 3,753,300 yuan on a year-on-year basis, with a growth rate of 1,125.52%, mainly because the
increase of the amount of exports in the last year has led to an increase of amount of export rebates in the current period;
8. Other cash paid relating to operating activities: a decrease of 24,517,900 yuan on a year-on-year basis, with a growth rate of
-30.29%, mainly due to the decrease of cash outflow related to expenses on a year-on-year basis;
9. Net cash flow from operating activities: a decrease of 283 million yuan on a year-on-year basis, with a growth rate of -155.14%,
mainly because the cash paid for the purchase of goods and the service payments has increased on a year-on-year basis;
10. Net cash received by disposing fixed assets, intangible assets and other long-term assets: an increase of 2,126,900 yuan on a
year-on-year basis, with a growth rate of 9,524.51%, mainly due to an increase of fixed assets income disposed in the current period
on a year-on-year basis;
11. Sub-total of cash inflows from investing activities: an increase of 2,126,900 yuan on a year-on-year basis, with a growth rate of
9,524.51%, mainly due to an increase of fixed asset income disposed in the current period on a year-on-year basis;
12. Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets: a decrease of 17,563,300
yuan, with a growth rate of -35.57%, mainly due to a decrease in expenditures for acquisition of fixed assets in the current period on
a year-on-year basis;
13. Other cash paid relating to investing activities: an increase of 26,502,400 yuan on a year-on-year basis, with a growth rate of
10,516.81%, mainly because the earnest money for transferring the stock rights of subsidiaries has been returned in the current
period;
14. Cash received by absorbing investments: a decrease of 1.47 million yuan on a year-on-year basis, with a growth rate of -100.00%,
mainly because there were investment funds paid to minority shareholders of subsidiaries at the same period of last year but there is
no such bus
